Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 24811-24820 Newer>

The Motley Fool July 25, 2007 Billy Fisher	Dueling Fools: Intuitive Surgical Bull Rebuttal On the bull side, experience, coupled with the company's future earnings and revenue prospects, may indicate that Intuitive Surgical has yet to reach its zenith.
The Motley Fool July 25, 2007 Lawrence Rothman	Chuck E. Cheese Caught in the Trap Chuck E. Cheese's quarterly earnings disappoint; the reasons for them disappoint even more.
The Motley Fool July 25, 2007 Charly Travers	Dueling Fools: Intuitive Surgical Bear Rebuttal On the bear side, Intuitive Surgical cannot continue to grow at an annual rate to make its stock a good value.
The Motley Fool July 25, 2007 Dave Mock	RF Micro Brewing Growth With investors feeling the last few quarters' hangover behind them, the market hoisted its glasses this morning, toasting RF Micro shares with a nearly 10% boost.
The Motley Fool July 25, 2007 Billy Fisher	Dueling Fools: Intuitive Surgical Bull For a company consistently growing its sales by 50% and maintaining healthy product margins, it's hard to imagine that this medical device maker's stock has yet met its peak.
The Motley Fool July 25, 2007	The Handle on Hansen Medical Investors, here is an interview with Frederic Moll, Hansen Medical's co-founder and CEO about the company's robotic catheter system, the advantages it offers, and growth opportunities.
The Motley Fool July 25, 2007 Tim Beyers	Hey, Ronald, Have You Lost Weight? Shedding extra pounds costs McDonald's some short-term profits. Investors, take note.
The Motley Fool July 25, 2007 Charly Travers	Dueling Fools: Intuitive Surgical Bear Investors, this is a great company -- it's just the wrong time to invest.
The Motley Fool July 25, 2007 Rich Smith	Foolish Forecast: Ford Finished? The auto maker is set to report second-quarter 2007 earnings. Investors, here is what you can expect to see.
The Motley Fool July 25, 2007 Brian Orelli	Hopeful Flu Production Technology From Baxter While the clinical trial demonstrating strong immunogenicity for the new vaccine is certainly good news, the continued development of the production technology is probably the more important item for investors.
<Older 24811-24820 Newer> Return to current articles.